|Home | About | Journals | Submit | Contact Us | Français|
We introduce a new method for brain MRI segmentation, called the auto context model (ACM), to segment the hippocampus automatically in 3D T1-weighted structural brain MRI scans of subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI). In a training phase, our algorithm used 21 hand-labeled segmentations to learn a classification rule for hippocampal versus non-hippocampal regions using a modified AdaBoost method, based on ~18,000 features (image intensity, position, image curvatures, image gradients, tissue classification maps of gray/white matter and CSF, and mean, standard deviation, and Haar filters of size 1×1×1 to 7×7×7). We linearly registered all brains to a standard template to devise a basic shape prior to capture the global shape of the hippocampus, defined as the pointwise summation of all the training masks. We also included curvature, gradient, mean, standard deviation, and Haar filters of the shape prior and the tissue classified images as features. During each iteration of ACM - our extension of AdaBoost - the Bayesian posterior distribution of the labeling was fed back in as an input, along with its neighborhood features, as new features for AdaBoost to use. In validation studies, we compared our results with hand-labeled segmentations by two experts. Using a leave-one-out approach and standard overlap and distance error metrics, our automated segmentations agreed well with human raters; any differences were comparable to differences between trained human raters. Our error metrics compare favorably with those previously reported for other automated hippocampal segmentations, suggesting the utility of the approach for large-scale studies.
Alzheimer's disease (AD) is the most common type of dementia, and affects over 5 million people in the United States alone (Jorm et al., 1987). The disease is associated with the pathological accumulation of amyloid plaques and neurofibrillary tangles in the brain, and first affects memory systems, progressing to involve language, affect, executive function, and all aspects of behavior. A major therapeutic goal is to assess whether treatments delay or resist disease progression in the brain before widespread cortical and subcortical damage occurs. For this, sensitive neuroimaging measures have been sought to quantify structural changes in the brain in early AD which are automated enough to permit large-scale studies of disease and the factors that affect it.
To track the disease process, several MRI- or PET-based imaging measures have been proposed. Many studies have sought optimal volumetric measures (e.g., of the hippocampus or entorhinal cortex) to differentiate normal aging from AD, and from mild cognitive impairment (MCI), a transitional state that carries a 4-6 fold increased risk of imminent decline to AD relative to the normal population (Petersen, 2000; Petersen et al., 2001; Petersen et al., 1999). A common biological marker of disease progression is morphological change in the hippocampus, assessed using volumetric measures (Jack et al., 1999; Kantarci and Jack, 2003) or by mapping the spatial distribution of atrophy in 3D (Apostolova et al., 2006a; Apostolova et al., 2006b; Csernansky et al., 1998; Frisoni et al., 2006; Thompson et al., 2004).
Using MRI at millimeter resolution, subtle hippocampal shape changes may be resolved. However, isolating the hippocampus in a large number of MRI scans is time-consuming, and most studies still rely on manual outlining guided by expert knowledge of the location and shape of each region of interest (ROI) (Apostolova et al., 2006a; Du et al., 2001). To accelerate epidemiological studies and clinical trials, this process should be automated. Some automated systems have been proposed for hippocampal segmentation (Barnes et al., 2004; Crum et al., 2001; Fischl et al., 2002; Hogan et al., 2000; Powell et al., 2008; Wang et al., 2007; Yushkevich et al., 2006), but none is yet widely used.
Pattern recognition techniques (Duda et al., 2001) offer a range of promising algorithms for automated subcortical segmentation. Most pattern recognition (or machine learning) algorithms attempt to assign a probability to a specific outcome. In image segmentation, image cues are pooled to determine with a specific probability whether each image voxel is part of an ROI (e.g., the hippocampus) or not. In pattern recognition, cues are usually referred to as features, and different pattern recognition algorithms combine these features in different ways. When using pattern recognition approaches, it is standard practice to divide a dataset into two non-overlapping classes, for training and testing. The training set is used to learn the patterns (e.g., estimate a function or decision rule for classifying voxels), and the testing set is used to validate how well new datasets can be classified, based on the patterns that were learned.
Since medical images are complex, many possible features may be created to represent each voxel. Given the large number of voxels in an MRI scan, computing and storing this amount of data may become unmanageable. For example, features may consist of image intensity, x, y, and z positions, image curvature, image gradients, or the output of any other general image filter. To overcome this problem, here we use a variant of a machine learning algorithm called AdaBoost (Freund and Schapire, 1997). AdaBoost is a weighted voting algorithm, which combines “weak learners” into a “strong learner.” A weak learner is any pattern recognition algorithm that guesses correctly greater than half of the time. At each iteration, AdaBoost selects a weak learner that minimizes the error for all voxels based on the classification of previously selected weak learners. Therefore, an incorrectly classified example at one iteration will receive more weight on subsequent iterations.
To segment the hippocampus in an MRI scan, here we use AdaBoost inside a new pattern recognition algorithm we call the auto context model (ACM). ACM is not specific to AdaBoost and may be used with any classification technique, but here we use it with AdaBoost, which has previously been found to be effective for subcortical segmentation in smaller samples of subjects (Morra et al., 2007; Quddus et al., 2005; Tu et al., 2007).
This paper presents a validation study of ACM using data from an Alzheimer's disease study. We show that this approach accurately captures the hippocampus and may therefore be useful in large scale studies of AD where manual tracing would be prohibitive.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) (Mueller et al., 2005a; Mueller et al., 2005b) is a large multi-site longitudinal MRI and FDG-PET (fluorodeoxyglucose positron emission tomography) study of 800 adults, ages 55 to 90, including 200 elderly controls, 400 subjects with mild cognitive impairment, and 200 patients with AD. The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public-private partnership. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials. The Principal Investigator of this initiative is Michael W. Weiner, M.D., VA Medical Center and University of California – San Francisco.
All subjects underwent thorough clinical/cognitive assessment at the time of scan acquisition. As part of each subject's cognitive evaluation, the Mini-Mental State Examination (MMSE) was administered to provide a global measure of cognitive status based on evaluation of five cognitive domains (Cockrell and Folstein, 1988; Folstein et al., 1975); scores of 24 or less (out of a maximum of 30) are generally consistent with dementia. Two versions of the Clinical Dementia Rating (CDR) were also used as a measure of dementia severity (Hughes et al., 1982; Morris, 1993). The global CDR represents the overall level of dementia, and a global CDR of 0, 0.5, 1, 2 and 3, respectively, indicate no dementia, very mild, mild, moderate, or severe dementia. The “sum-of-boxes” CDR score is the sum of 6 scores assessing different areas of cognitive function: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The sum of these scores ranges from 0 (no dementia) to 18 (very severe dementia). Table 1 shows the clinical scores and demographic measures for our sample. The elderly normal subjects in our sample had MMSE scores between 26 and 30, a global CDR of 0, a sum-of-boxes CDR between 0 and 0.5, and no other signs of MCI or other forms of dementia. The MCI subjects had MMSE scores ranging from 24 to 30, a global CDR of 0.5, a sum-of-boxes CDR score between 0.5 and 5, and mild memory complaints. Memory impairment was assessed via education-adjusted scores on the Wechsler Memory Scale - Logical Memory II (Wechsler, 1987). All AD patients met NINCDS/ADRDA criteria for probable AD (McKhann et al., 1984) with an MMSE score between 20 and 26, a global CDR between 0.5 and 1, and a sum-of-boxes CDR between 1.0 and 9.0. As such, these subjects would be considered as having mild, but not severe, AD. Detailed exclusion criteria, e.g., regarding concurrent use of psychoactive medications, may be found in the ADNI protocol (page 29, http://www.adni-info.org/images/stories/Documentation/adni_protocol_03.02.2005_ss.pdf). Briefly, subjects were excluded if they had any serious neurological disease other than incipient AD, any history of brain lesions or head trauma, or psychoactive medication use (including antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.).
The study was conducted according to Good Clinical Practice, the Declaration of Helsinki and U.S. 21 CFR Part 50-Protection of Human Subjects, and Part 56-Institutional Review Boards. Written informed consent for the study was obtained from all participants before protocol-specific procedures, including cognitive testing, were performed.
As noted earlier, when using a pattern recognition approach to identify structures in images, two non-overlapping sets of images must be defined, for training and testing (Morra et al., 2007; Powell et al., 2008). The training set consists of a small sample of brain images, representative of the entire dataset, which are manually traced by experts. The testing set is a group of brain images that are to be segmented by the algorithm, but have not been used for training the algorithm. Our training set consisted of 21 brain images, from 7 healthy elderly individuals, 7 individuals with MCI, and 7 individuals with AD. Since we only have manual tracings of these brains, we construct our testing set using a leave-one-out approach. For testing, we train 21 models, each one ignoring one subject (i.e., not using that subject for training), and we then test each model on the subject that it ignored. This gives a testing set of the same 21 brains, each with a ground truth segmentation for comparison purposes; even so, it ensures the independence of the training and testing sets, a common requirement in validating computer vision methods. We chose to train on 21 subjects because this number was sufficient in previous studies that varied the training sample size (Morra et al., 2007); smaller training sets degraded segmentation performance. Each of the three groups (AD, MCI, and controls) were age- and gender-matched as closely as possible as shown in Table 1.
All subjects were scanned with a standardized MRI protocol, developed after a major effort evaluating and comparing 3D T1-weighted sequences for morphometric analyses (Jack et al., 2007; Leow et al., 2006).
High-resolution structural brain MRI scans were acquired at multiple ADNI sites using 1.5 Tesla MRI scanners manufactured by General Electric Healthcare and Siemens Medical Solutions. ADNI also collects data at 3.0 T from a subset of subjects, but to avoid having to model field strength effects in this initial study, only 1.5 T images were used. All scans were collected according to the standard ADNI MRI protocol (http://www.loni.ucla.edu/ADNI/Research/Cores/index.shtml). For each subject, two T1-weighted MRI scans were collected using a sagittal 3D MP-RAGE sequence. Typical 1.5 T acquisition parameters are repetition time (TR) of 2400 ms, minimum full excitation time (TE), inversion time (TI) of 1000 ms, flip angle of 8°, 24 cm field of view, acquisition matrix was 192×192×166 in the x-, y-, and z- dimensions yielding a voxel size of 1.25×1.25×1.2 mm3 (Jack et al., 2007). In plane, zero-filled reconstruction yielded a 256×256 matrix for a reconstructed voxel size of 0.9375×0.9375×1.2 mm3. The ADNI MRI quality control center at the Mayo Clinic (in Rochester, MN, USA) selected the MP-RAGE image with higher quality based on standardized criteria (Jack et al., 2007). Additional phantom-based geometric corrections were applied to ensure spatial calibration was kept within a specific tolerance level for each scanner involved in the ADNI study (Gunter et al., 2006).
Additional image corrections were also applied, using a processing pipeline at the Mayo Clinic, consisting of: (1) a procedure termed GradWarp for correction of geometric distortion due to gradient non-linearity (Jovicich et al., 2006), (2) a “B1-correction”, to adjust for image intensity non-uniformity using B1 calibration scans (Jack et al., 2007), (3) “N3” bias field correction, for reducing intensity inhomogeneity (Sled et al., 1998), and (4) geometrical scaling, according to a phantom scan acquired for each subject (Jack et al., 2007), to adjust for scanner- and session-specific calibration errors. In addition to the original uncorrected image files, images with all of these corrections already applied (GradWarp, B1, phantom scaling, and N3) are available to the general scientific community, as described at http://www.loni.ucla.edu/ADNI. Ongoing studies are examining the influence of N3 parameter settings on measures obtained from ADNI scans (Boyes et al., 2007).
To adjust for global differences in brain positioning and scale across individuals, all scans were linearly registered to the stereotactic space defined by the International Consortium for Brain Mapping (ICBM-53) (Mazziotta et al., 2001) with a 9-parameter (9P) transformation (3 translations, 3 rotations, 3 scales) using the Minctracc algorithm (Collins et al., 1994). Globally aligned images were resampled in an isotropic space of 220 voxels along each axis (x, y, and z) with a final voxel size of 1 mm3.
All discriminative pattern recognition techniques involve taking some set of examples with a label and learning a pattern based on those examples. Usually the examples are themselves each a vector of problem-specific information, referred to as features. Each feature must be calculable for each example (for implementation purposes, hopefully quickly), and the features should provide some insight into the classification task. For medical image segmentation, these features are derived at each voxel in all brains, so at each voxel, there exists a vector for which each entry is a specific feature evaluated at that voxel.
In our case, we chose features based on image intensity, tissue classification maps of gray matter, white matter, and CSF (binary maps obtained by an unsupervised classifier, PVC (partial volume classifier; (Shattuck et al., 2001))) and neighborhood-based features derived from the tissue classified maps, x, y, and z positions (along with combinations of positions such as x+y or x*z), curvature filters, gradient filters, mean filters, standard deviation filters, and Haar filters (Viola and Jones, 2004) of sizes varying from 1×1×1 to x, y, z positions were determined using stereotaxic coordinates after spatial normalization to the standard space. In addition to these features, we exploited the fact that all the brains had been registered to devise a basic shape prior to capture the global shape of the hippocampus. Our shape prior was defined as the pointwise summation of all the training masks. Differential positional effects in the x, y, and z positions are therefore captured by using a shape prior, and also by including products of x, y, and z voxel indices as features.
Since brain MRIs consist of many voxels, the product of the number of features and the number of voxels can be exceedingly large. However, because all of our brains are registered to the same template, the hippocampi will always appear in approximately the same localized region. We can exploit this fact to reduce our search space by constructing a bounding box, and only classifying examples (feature vectors at each voxel) for voxels that fall in this bounding box. To define the box we scan over all the training examples and find the minimum and maximum x, y, z positions of the hippocampus. Next, we add the size of the largest neighborhood feature (in this case, 7 voxels) and some additional voxels to cope with as yet unseen testing brains (in this case, 10 voxels). Then training commences on only voxels inside of this box. Also, when testing a new brain, only voxels inside this box are classified, all others are assumed negative. All features are computed at each voxel, rather than averaging them over the bounding box. When classifying each voxel, features such as image intensity, image gradient, and tissue classification are computed voxel-wise. The number of features is approximately 18,000 per voxel, and the same set of candidate features are available to the classifier at every voxel, so the number of features does not depend on the size of the bounding box.
AdaBoost is a machine learning method that uses a training set of data to develop rules for classifying future data; it combines individual rules that do not work especially well into a pool of rules that can be used to more accurately classify new data. The overall classifier can greatly outperform the component classifiers. The component classifiers are often called “weak learners”, as they may perform only slightly better than random; for example, a classifier of hippocampal voxels based on the binary feature “voxel is gray matter” could classify the hippocampus only slightly better than chance (i.e., 50% correct), as there are many nonhippocampal gray matter voxels. AdaBoost iteratively selects weak learners, h(x), from a candidate pool and combines them into a strong learner, H(x) (Freund and Schapire, 1997). In what follows, an example is defined as the feature vector at a voxel in the training dataset, with its associated classification; a weak learner classifies example voxels as belonging to the hippocampus or not belonging to the hippocampus. When classifying an example, a weak learner gives a binary output value of +1 for example voxels that it regards as positive (i.e., in the hippocampus) and −1 for example voxels it regards as negative (i.e., outside the hippocampus).
Figure 1 gives an overview of the AdaBoost algorithm. In our implementation, labeling the hippocampus is formulated as a two-class classification problem, in which the training data consists of input vectors of features, x1…xN , also called examples, and associated labels, yi. The components of the features are the outputs of the Haar filters, intensity measures, positions, and other feature detectors detailed earlier. The training phase of AdaBoost attempts to find the best combination of classifiers. Each data point, or example, is initially given a weight, D1(i). The weighting parameter for each data point is initially set to 1/N for all data points.
At this point, the construction of the set of weak learners hj (of size J) needs to be defined. We define a weak learner to be any feature, a threshold, and a boolean function representing whether or not observations above that threshold are positive (belong to the ROI) or negative (do not belong to the ROI). Therefore, our weak learner selects the feature that best separates the data into positive and negative examples given Dt. In order to do this, two histograms are constructed for each feature based on Dt, one that is only the positive examples, and another that is only the negative examples, these are then normalized and converted into cumulative distribution functions (CDFs). Finally, the threshold that minimizes the error based on these CDFs is chosen, and the lowest error over all features determines which weak learner is selected.
More formally, as detailed in Figure 1, at each stage t of the algorithm (t = 1 to T), AdaBoost trains a new weak learner in which the weighting coefficients, Dt(i), on the example data points are adjusted to give greater weight to the previously misclassified data points. In Figure 1, εj is the total error of the jth weak learner, determined by counting up all the examples misclassified, 1(yi ≠ hj(xi)), weighted by their current weights at time t, Dt(i). As such, they are weighted measures of the error rates of the weak learners. The best weak learner for stage t is the one with the lowest error, εt. This learner is based on a feature that is most “independent” of the previous learners. The best weak learner at each step is chosen from the full set of weak learners, not just from the new ones computed in successive steps by AdaBoost. The coefficient αt = (1/2) log((1 − εt) / εt) is defined to be a weighting coefficient for the t-th weak learner, which favors learners with very low error. The key to AdaBoost is that the influence of each example in the training set is re-weighted using the following rule: Dt exp(−αtyiht (xi)) / Zt , with Zt a normalizer defined in Figure 1, chosen so that the Dt+1(i) will be a probability distribution, i.e., sum to 1 over all examples xi. This re-weighting emphasizes examples that were wrongly labeled at the prior iteration. Successive classifiers are therefore forced to prioritize examples that were incorrectly classified, and these data points receive increasing priority, Dt(i). The formula for αt chosen such that it is the unique αt that minimizes Zt analytically, by satisfying dZt (αt) / dαt = 0 ; picked in this way αt is guaranteed to minimize Zt. The final vote H(x) is based on a thresholded weighted sum of all weak learners (Figure 1).
Because of the large number of examples to be classified, instead of using AdaBoost just once, a cascade was created, where at each node in the cascade examples that are clearly negative are discarded (a probability below 0.1). This allows the classifier to use different features for examples that are difficult to classify. The value of 0.1 was chosen because it was empirically shown to give good results in our other studies (Morra et al., 2007).
Friedman et al. (Friedman et al., 2000) noted that the update rule for weights (the “boosting” steps) in AdaBoost can be given a probabilistic interpretation, i.e. it can be derived by assuming that the goal is to sequentially minimize an exponential error function. Given a linear combination of weak learners , then the exponential error of a mislabeling may be defined as , where yi are the training set target values. If we wish to minimize E by optimizing the weak learner , then it can be shown that the best re-weighting of the examples is given by the update rule for Dt+1(i) (Friedman et al., 2000). Two comments are necessary: first, other AdaBoost variants have proposed altering the exponential error function, which AdaBoost minimizes, to be the cross-entropy, which is the log-likelihood of a well-defined probabilistic model and generalizes to the case of K > 2 classes (Friedman et al., 2000); and second, if the exponential error function is used, AdaBoost will find its variational minimizer over all the functions in the span of the weak learners. In fact, AdaBoost iteratively seeks a minimizer of the expected exponential error
and arrives at the final classification by constrained minimization. Although minimization of the number of classification errors may seem like a better goal, in general the problem is intractable (Hoffgen and Simon, 1992), so it is conventional to minimize some other nonnegative loss function such as E. The process of selecting αt and may be interpreted as a single optimization step minimizing the upper bound on the empirical error; improvement of the bound is guaranteed, so long as εt< 1/2, and choosing ht and αt in this way results in the greatest decrease in the exponential loss, in the space of weak learners, and converges to the infimum of the exponential loss (Collins et al., 2002).
Also, traditionally, AdaBoost does not define the term, and just uses the sign of as the strong learner. However, when using ACM, it is necessary that the output not be a decision rule, but rather a value in the range [0 1] representing the confidence that the given example is positive or negative. Therefore, we employ the LogOdds transform (Apostolova et al., 2007; Pohl et al., 2007) to map the interval (-∞ ∞) to (0 1). The LogOdds transform essentially makes the optimal classifier produce Bayesian maximum likelihood estimates of the labeling, under the premise of using an exponential loss function.
As noted by Collins et al. (Collins et al., 2002), instead of using as a classification rule, one can consider that the yi are generated through a generative probability law, using to estimate the probability of the associated label yi. A common way to do this is to pass through a logistic function, and use the estimate The likelihood of the labels occurring in the training set is then . Maximizing this likelihood is equivalent to minimizing the log loss of this model .
According to Bayesian theory, the goal of pattern recognition algorithms is to correctly model the posterior distribution defined as P(y = ±1 | x) = P(x | y = ±1)P(y = ±1) / P(x). AdaBoost itself may be regarded as providing an approximation to this probability (Shi et al., 2005), and since we are using a shape prior, AdaBoost models the combination of the conditional and prior probabilities (the marginal probability is a constant). In the simplest case, Bayes' rule looks at each example independently of all others. However, in our case, and in fact in most image segmentation cases, the posterior distribution of nearby voxels should influence each other. In any pattern recognition algorithm that attempts to model the Bayesian posterior, this information is mostly ignored, although some Markov methods have been proposed that make use of empirically-estimated prior distributions on the joint labeling of contiguous voxels (Fischl et al., 2001). Here, we include this information by modeling P(y = ±1 | x, xneighbors) = P(x, xneighbors | y = ±1)P(y = ±1) / P(x, xneighbors).
ACM attempts to model the above distribution iteratively; a description is given in Figure 2.
In our context, H is the cascade of AdaBoosts without the final binary classification step. In order to improve ACM, instead of starting P1 with a uniform distribution, we instead start with our shape prior. Also, in order to give more information about the classifications of neighboring voxels, when running AdaBoost inside of ACM, we included neighborhood features defined on Pt. Specifically we included the same Haar, curvature, gradient, mean, and standard deviation filters on the posterior map as we do on the images.
We can prove that for each iteration of ACM, the error is monotonically decreasing. Define the error of the classification algorithm (in our case a cascade of AdaBoosts) at iteration t to be εt, we then prove that εt ≤ εt−1. First, we define pt (yi | xi) to be the probability change associated with iteration t of ACM. Next, since Pt−1 includes all previous iterations of ACM, we can write and . In the trivial case, pt (yi | xi, Pt−1(i)) = Pt−1(i) yi by simply choosing pt to be a uniform distribution. However, since it has been shown that AdaBoost decreases the error at every iteration, it must choose weak learners that decrease pt, so therefore εt ≤ εt−1.
When implementing our method there are a number of parameters that must be set, but very few that need to be tweaked. We used approximately 18,000 features in our feature pool. This includes both features based on the images, and those based on the posterior maps from ACM. We chose to run each AdaBoost for 200 iterations, obtaining 200 weak learners per AdaBoost cascade node, a cascade depth of two nodes, and five ACM iterations. This leads to running ten iterations of AdaBoost during the training phase. Overall, training takes about twelve hours. Even so, testing is very short, taking less than one minute to segment the hippocampus on a new brain image.
It is also of interest to note which features AdaBoost chose in order to obtain insight into the segmentation process. During the first iteration of ACM, AdaBoost chose mostly features based on the Haar filter and based on the tissue classified image (i.e., binary maps of gray and white matter and CSF). Later iterations of ACM choose mostly Haar filter outputs and mean filter outputs based on the previously selected posterior distribution, which means that neighboring voxels are influencing each other, as is to be expected. These features are not totally independent, since most are based on the same underlying image intensities; however each adds some classification ability to the final decision rule. An advantage of this approach is that the algorithm does not have to rely on the same small subset of features when trained on different training sets, and can select different features when trained on different examples, if they are optimal. As with other boosting methods, it is not expected or even desirable that the same feature sets be recovered when analyzing images from different sources, and it is not expected that each of the features used has good classification ability in its own right; in fact, any boosting method uses so-called ‘weak learners’, with individual classification performance only slightly better than chance, and combines them effectively using the boosting strategy.
When validating a machine learning approach it is essential to examine error metrics on both the training and testing sets. A test set independent of the training set is vital in machine learning, in order to show the effectiveness of a classifier on data totally withheld from the training set. Since we used 21 hand-labeled brains to train the algorithm, we employed a leave-one-out analysis to guarantee a separation between the training and testing sets. In order to put our error metrics in context and decide whether they were acceptable for the application, we had a second independent expert rater trace the same 21 brains. We were then able to create a triangle of comparisons as shown in Figure 3, in which the algorithm's segmentations can be compared with those of the human rater who trained the algorithm (rater 1; A.G.) and with those of an independent rater (rater 2; C.A.) who did not train the algorithm.
In order to show agreement with a human expert not involved with training the algorithm, we only trained our algorithm on manual segmentations from rater 1 and were still able to achieve good segmentation results that agreed well with rater 2's manual tracings. We emphasize that the validation against rater 1 is also an independent validation in the sense that our algorithm was classifying images that it was not trained on (i.e. a leave-one-out approach).
Secondly, we further validated our approach using volumetric results of three kinds. We hypothesized that hippocampal volume would decrease as the disease progresses further, and verified this by comparing mean volumes in groups of controls, MCI subjects, and AD patients. We also examined whether, in the full sample, hippocampal volume was correlated with clinical measurements of cognitive impairment; encouragingly, we found that measures from our segmentations correlated more strongly with cognition, in the hippocampus, than measures from a popular technique for quantification of brain atrophy, tensor-based morphometry, which is closely related to voxel-based morphometry.
Finally, since longitudinal follow-up scans were available for the individuals tested in this paper, we used scans taken six months later to assess the longitudinal stability of the segmentations of the same subject. We showed that the amount of hippocampal volume change was consistent with prior reports in the literature.
To assess our segmentations' performance, we first define a number of error metrics based on the following definitions: A, the ground truth segmentation, and B, the testing segmentation. Additionally, we define d(a,b) as the Euclidean distance between points a and b.
First, Table 2 presents our segmentation performance on the training set. For this analysis, we used all 21 brains as training data, and tested on all 21 brains. These performance results on the training set represent an upper bound for the expected accuracy on the testing set. Next, we used our leave-one-out approach to obtain testing metrics comparing our results to rater 1 (leg “b” in Figure 3), shown in Table 3. Table 4 compares our method with rater 2 (leg “c” in Figure 3), again using the leave-one-out technique. Finally, we compared the two human raters directly with one another (leg “a” in Figure 3) in Table 5.
The first thing to note is that the error metrics from the training and test sets are very close to each other, with the testing metrics being slightly worse than the training metrics (which is to be expected). This shows that ACM is not memorizing the data, but instead learning the underlying structure of the hippocampus. Next, our algorithm shows only a small difference in the error metrics as opposed to the difference between the two human raters. Specifically, if Table 4 and Table 5 are compared, the relative overlap between two human raters is on average 74.9% for the left and 74.3% for the right hippocampus (Table 5), while the relative overlap between the algorithm and a rater not involved in training it was 75.4% for the left and 71.9% for the right hippocampus (Table 4). This shows that the errors in our algorithm are comparable to the differences between two raters. In terms of precision, the agreement between the two human raters is about 3% higher than the agreement between the algorithm and the rater not used to train it, with all values in the 83-89% range. For recall, the algorithm agrees with the 2nd rater at least as well as the 1st rater agrees with the 2nd rater, with all values in the 82-86% range. The only metric for which the human raters agree with each other more than they do with the algorithm is the mean error (see Table 4 and Table 5), but for that metric agreement is very high between all three suggesting that any biases are very small.
To further compare the performance of our approach with other segmentation methods, in Table 6 we present error metrics from three other papers that report either fully or semi-automated hippocampal segmentations. We present these only to show that ours is within the same range as other automated approaches. Since each study uses a different set of scans, an exact comparison is not possible.
Figure 4 shows an example brain from the test set, with the right and left hippocampi overlaid in yellow and green. There is good differentiation of the hippocampus from the surrounding amygdala, overlying CSF, and adjacent white matter, and the traces are spatially smooth, simply connected, and visually resemble manual segmentations by experts. This image was chosen at random from the test set, and is representative of the segmentation accuracy obtainable on the test images.
Table 7 shows that the inter-rater r (intraclass correlation) between the two raters' hippocampal volumes and the volumes obtained from our algorithm's segmentations are comparable. Although the inter-rater r is lower when comparing our approach to either rater versus the difference between the two raters, the intraclass correlation is high, and, as expected, statistically significant on both sides. For all of the tests in Table 7, we trained the algorithm only on segmentations from rater 1, and this is one reason why there is a slightly higher correlation observed with rater 1 than with rater 2.
Next, we present a disease-based validation technique, based on the premise that a necessary but not sufficient condition for a valid classifier is that it differentiates group mean hippocampal volumes between AD, MCI and controls. Since it is well-known that reductions in hippocampal volume are associated with declining cognitive function (Jack et al., 1999), we showed that our method is accurately capturing known mean volumetric differences between subgroups of interest with different stages of dementia (controls, MCI, and AD). Due to the limited sample size (N = 21), we pooled left and right hippocampal volumes together for some of these results. Volumetric summaries were computed using the segmentations obtained in the leave-one-out testing analysis.
Figure 5 and Table 8 show that there is a sequential reduction in volume between controls, MCI, and AD subjects, consistent with many prior studies (Convit et al., 1997). This shows that the brain MRIs we are working with show the expected profile of volumetric effects with disease progression, and that the segmentation approach is measuring hippocampal volumes with low enough methodological error to differentiate the 3 diagnostic groups, at least at the group level, in a very small sample.
Table 9: shows strong and significant positive correlations between hippocampal volume and MMSE scores (r = 0.587 for the average of the left and right hippocampal volumes; p < 0.01), and with sum of boxes CDR scores, for both the left and right, and mean hippocampal volumes (r = −0.642 for the mean volume, p < 0.01). Correlations are high (around 0.6) when the average of the left and right hippocampal volumes is measured, suggesting that the hippocampal volumes explain a significant proportion of the variation in clinical decline. Although these associations are known, it provides evidence that the classifier error is low enough to allow their detection in small samples. Each of these values is significant despite the very small sample size, further confirming that our method is capable of capturing disease-associated hippocampal degeneration.
In a previous cross-sectional study on the ADNI dataset, we used tensor-based morphometry (TBM) to analyze brain differences associated with different stages of disease progression (Hua et al., 2008). TBM is a method based on high-dimensional image registration, which derives information on regional volumetric differences from a deformation field that aligns the images. TBM and voxel-based morphometry (VBM (Ashburner and Friston, 2000)) are closely linked and each measures voxelwise expansion (or contraction) of the brain as compared to a minimal deformation template, which represents the mean anatomy of the subjects (Lepore et al., 2007).
Voxel-based morphometry (Davatzikos et al., 2001; Good et al., 2001) is a related approach that modulates the voxel intensity of a set of spatially normalized gray matter maps by the local expansion factor of a 3D deformation field that aligns each brain to a standard brain template.
Although TBM has proven useful in quantifying brain atrophy over time in 3D (Leow et al., 2005a; Studholme et al., 2004; Teipel et al., 2007), in cross-sectional studies TBM can be less effective for quantifying volumetric differences in small brain regions (such as the hippocampus) when the ROI is defined on the minimal deformation template.
This is to be expected, as TBM may be considered a rudimentary hippocampal segmentation approach that works by fluidly deforming a mean anatomical template onto the target image – the criteria to guide accurate segmentations are typically limited to measures of agreement in image intensities, such as the mutual information (Leow et al., 2005b; Viola and Wells, 1995). Table 10 shows the correlation between hippocampal volume (as measured with TBM) and MMSE and sum of boxes CDR scores. Note that none of the correlations is even significant in this small sample, and the measures compare poorly with those shown in Table 9. This suggests that our direct segmentation of hippocampal anatomy via voxel-level classification is better correlated with cognition than measures we previously obtained using a deformation-based morphometry method.
As a final validation approach, we segmented a set of six-month follow-up scans, acquired using an identical imaging protocol, for the individuals whose baseline scans were analyzed in this paper. At the time of writing, six-month follow-up scans were available for 18 of the 21 subjects analyzed in this paper, including 6 AD patients, 5 MCI patients, and 7 control subjects. Due to the very small sample size (especially in the AD and MCI groups) and short interval, we present this analysis to show that our algorithm is reproducible, giving relatively consistent hippocampal volumes over a short interval, when minimal hippocampal volume loss is expected. Table 11 shows that there is minimal loss over 6 months, which is to be expected. We note that this change represents a combination of biological changes and the methodological errors in segmentation, which derive partly from the algorithm and partly from the fact that the image acquisition is not perfectly reproducible. As these sources of methodological error are expected to be small and additive, the fact that the mean change is near 1.5% for the left and 0% for the right hippocampus is in line with expectation. Given that some small biological change is also occurring, this suggests good longitudinal stability for the volume measurements obtained by our algorithm.
In this study, we have demonstrated that ACM is an effective method for segmenting the hippocampus. There were three major findings. First, the agreement between our algorithm and two different human raters was comparable with their agreement with each other, which is a reasonable target for segmentation accuracy given that even trained human raters do not entirely agree on the labeling of all hippocampal voxels. Second, we found that the agreement with a rater not involved with training the algorithm was almost as good as the agreement with the rater who trained it, suggesting acceptable inter-rater reliability versus expert human raters. Third, we found that the hippocampal volumes segmented by our algorithm correlated well with cognitive and clinical ratings of dementia severity, which is an important characteristic for an automated volume measurement algorithm. For an algorithm to be useable in a drug trial context for the quantification of brain atrophy, it is necessary for the automatically measured volumes to replicate known differences in mean hippocampal volume between AD, MCI, and controls, and it is also desirable for the measures to be accurate enough to correlate with clinical measures of disease burden as they did here in a small sample (21 subjects; 7 of each diagnosis). In a further demonstration of longitudinal stability, we found that the change detected in 6-month repeat scans was around 0-1.5% for a group of 18 subjects. As this group was heterogeneous with regard to diagnosis and the time interval small, the intent of the experiment was merely to show that the mean changes were small, and within the range of expected biological variation.
This study is representative of several current research efforts that use automated methods to measure hippocampal atrophy in AD, including large diffeomorphic metric mapping (Csernansky et al., 2004; Wang et al., 2007), volumetric analysis (Geuze et al., 2005), and fluid registration (van de Pol et al., 2007). For purposes of comparison with our technique, we computed hippocampal volume measures from a related technique, known as tensor-based morphometry (TBM), which estimates anatomical structure volumes from a deformation transform that re-shapes a mean anatomical template onto each individual scan. Our TBM measures correlated poorly with cognitive assessments, although clearly in such a small sample the power to detect such associations is severely limited. Some reasons why TBM may not be optimal for hippocampal volumetric study are detailed in Hua et al. (2008) and (Apostolova et al., 2006a; Becker et al., 2006; Frisoni et al., 2006). TBM is typically best for assessing differences at a scale greater than 3-4 mm (the typical resolution of the spectral representation used to compute the deformation field) (Hua et al., 2008; Leow et al., 2005a). For smaller-scale effects, direct modeling of the structure, e.g. using surface-based geometrical methods, may offer additional statistical power to detect sub-regional differences. Even then, it may not be possible to achieve accurate regional measurements of atrophy, especially in small regions such as the hippocampus, since that would assume a locally highly accurate registration. Direct assessments of hippocampal volume by our ACM algorithm correlated better than TBM did with clinical dementia ratings and MMSE scores, and explained a substantial proportion of their variance even in this relatively small sample (r ~ 0.6; p < 0.01; N = 21). Conversely, a relative advantage of TBM, and other voxel-based mapping approaches, such as voxel-based morphometry, is that they map the profile of atrophy throughout the brain without the need for explicit segmentation of anatomical structures. VBM has been widely used in Alzheimer's disease studies, and does not rely on an explicit segmentation of hippocampal anatomy in each scan, other than that which is implied in a voxel-based analysis by aligning scans to a common template. Chetelat et al. (Chetelat et al., 2005), for example, tracked gray matter loss with VBM in a longitudinal study of 18 MCI patients. Whitwell and colleagues (Whitwell et al., 2007) demonstrated the profile of gray matter loss over three years in 63 MCI subjects, and Good et al. (Good et al., 2002) compared VBM to region-of-interest analysis and showed that they compared favorably in detecting structural differences in Alzheimer's disease.
The machine learning approach presented here selects features based on a training set of expert segmentations, so it may generalize well for segmenting other subcortical structures, such as the thalamus and basal ganglia. The next step will be to further examine ACM with AdaBoost by evaluating it on a large sample, and examining its performance on other subcortical structures.
Data used in preparing this article were obtained from the Alzheimer's Disease Neuroimaging Initiative database (INDA/ude.alcu.inol.www). Many ADNI investigators therefore contributed to the design and implementation of ADNI or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators is available at lmths.noitatiC_INDA/noitaroballoC/INDA/ude.alcu.inol.www. This work was primarily funded by the ADNI (Principal Investigator: Michael Weiner; NIH grant number U01 AG024904). ADNI is funded by the National Institute of Aging, the National Institute of Biomedical Imaging and Bioengineering (NIBIB), and the Foundation for the National Institutes of Health, through generous contributions from the following companies and organizations: Pfizer Inc., Wyeth Research, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Merck & Co. Inc., AstraZeneca AB, Novartis Pharmaceuticals Corporation, the Alzheimer's Association, Eisai Global Clinical Development, Elan Corporation plc, Forest Laboratories, and the Institute for the Study of Aging (ISOA), with participation from the U.S. Food and Drug Administration. The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. Algorithm development for this study was also funded by the NIA, NIBIB, the National Library of Medicine, and the National Center for Research Resources (AG016570, EB01651, LM05639, RR019771 to PT). We thank the members of the ADNI Imaging Core for their contributions to the image pre-processing and the ADNI project.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.